Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma

Session Details

Session Title: Presented Poster Session: Glaucoma I

Venue: Poster Village: Pod 3

First Author: : J.Kwon SOUTH KOREA

Co Author(s): :    J. Shin                       

Abstract Details

Purpose:

To compare the lipid layer thickness (LLT) via the LipiView® Ocular Surface Interferometer (TearScience® Inc, Morrisville, NC) between the eye treated with glaucoma medication and untreated normal eye in the unilateral glaucoma patients, and evaluate the effect of topical glaucoma medication on the LLT parameters in glaucoma eyes.

Setting:

Cross-sectional comparative study

Methods:

The participants were glaucoma patients in the unilateral eye treated with topical glaucoma medications for more than 12 months. Three LLT parameters (average, minimum, and maximum) obtained by the LipiView® were compared between the glaucomatous eye and normal eye. Statistical analysis used: The factors associated with LLT parameters in the eyes treated with glaucoma medication were investigated with multiple regression analysis.

Results:

Thirty patients with unilateral NTG were enrolled in the present study. Lipid layer average, minimum, and maximum were 64.83±16.50, 51.63±16.73, and 82.53±20.62 in glaucomatous eyes, 77.26±17.81, 62.83±20.99, and 86.13±15.42 in normal eyes. Lipid layer average and minimum were significantly thinner than those in normal eyes (P<0.001, P<0.001, respectively). Longer duration of glaucoma eyedrops and greater number of glaucoma medications were associated with the lower LLT average (β=-0.456, P<0.001, β=-8.517, P=0.003, respectively), and increasing glaucoma medications have significant correlation with lower LLT minimum in glaucoma eyes (β=-8.814, P=0.026)

Conclusions:

The present study highlight that the glaucoma patients with long-term glaucoma treatments or using many glaucoma eyedrops need to be interested in LLT parameters which was useful for objectively assessing ocular surface disease.

Financial Disclosure:

None